Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The War on Generics - Part I

This article was originally published in RPM Report

Executive Summary

Generic drug companies are riding high after the largest generic launch ever (Zocor) and arguably the cleverest (Plavix). But brand companies are fighting back, and they may succeed in taking away the biggest incentive fueling patent challenges.

Related Content

FTC Study of Authorized Generics Gets Off the Ground: Now What?
Betting Generic: Part D, Patents and Proteins Drive Investment Surge
Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning
Reinventing Pharmacy: The Price Increase for Caremark Could Be a Price Decrease for Manufacturers
The War on Generics - Part II
Pfizer's Change Management: Unfamiliar Faces
CMS Takes Sides in the Statin Wars
Generics Attract Royalty Funding Options Too
Unsettling Developments for Plavix
Generics in Italy: Angelini's Positioning Play


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts